G 2/21 does not permit armchair inventing (T 0258/21)
The IPKat
OCTOBER 31, 2023
The recent decision in T 0258/21 , by contrast, is the first interpretation of G 2/21 leading to a finding of a lack of inventive step in view of an inadequate disclosure of the purported technical effect. Clevidipine is a anti-hypertensive drug marketed by Chiesi as Cleviprex.
Let's personalize your content